Thank you for contacting health at hand.
There are two types of hormone treatment – aromatase inhibitors e.g (letrozole) which are only given to postmenopausal women, and tamoxifen, which is most often used in premenopausal women, but can also be used in the treatment of postmenopausal women.
For the treatment of breast cancer (licensed use), the dosage of Tamoxifen range is 20–40 mg taken twice a day or as a single daily dose. Treatment is usually continued for at least 5 years.
According to evidence based data approximately, 5 years of tamoxifen therapy improved 10-year survival in women with estrogen receptor-positive or unknown, node-positive breast cancer.
Adjuvant treatment with tamoxifen for 10 years compared with 5 years resulted in a significant reduction in the rate of recurrence and in breast cancer mortality in a large trial. Similar results were found in a study of long-term therapy with tamoxifen (10 years) which was associated with a 23% relative reduction in relapse and a relatively longer 7-year disease-free survival compared with short-term therapy (3 years) in patients with early breast cancer.
Furthermore, according to NHS choices there had been headline confusion on the BBC website over whether treatment should be continued for 10 to 15 years. This may be linked to the fact that some patients had taken 5 years of tamoxifen initially, followed by 10 years of treatment with an aromatase inhibitor.
If you would like to read further on this matter please follow this link:
Tamoxifen - NHS News
We hope that is of some assistance to you.
Answered by the Health at Hand nurses
We’re here to help you take care of your health - whenever you need us, wherever you are, whether you're an AXA PPP healthcare member or not.
Our Ask the Expert service allows you to ask our team of friendly and experienced nurses, midwives, counsellors and pharmacists about any health topic.